Oncology
Adjuvant CDK4/6 Benefits Diverge in Early Breast Cancer
A meta-analysis found invasive disease-free survival gains with adjuvant abemaciclib and ribociclib, but not palbociclib, in HR-positive, HER2-negative early breast cancer.
Rayan Salih · September 2, 2026 · 7 min